Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings ... Read our full analysis here, it’s free. This quarter, analysts are expecting Incyte’s revenue to ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of ...

I first met Wincy Ong in the buzzing world of advertising and PR, a place where creativity and storytelling intertwine with the art of persuasion. Back then, we were just two professionals navigating ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per ...

Recall that in Q3 and Q4 2023, we saw a significant increase in the number of Medicare Part D patients receiving free product. As we anticipated, these patients returned to paid demand in 2024.

Before you invest in Incyte Corporation (INCY), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

Shares of Incyte (NASDAQ:INCY) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. The biotech company reported that Q4 revenue rose 16% year-over-year to $1 ...